Evidence map›Paper›PMID 42580835›Full record

Trial reportBMJ open2026

Obesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2).

Kristin K Clemens, Jennifer Irwin, Michael Chiu, Stephanie Dixon, Natalie J Bendo, Phil Varughese, Amanda J Vinson, Heather Lapier, David Attalla, Jaclyn Ernst and 7 more

Registry-linked trialAbstract readRandomized Controlled TrialPragmatic Clinical Trial
PubMed Publisher
In one paragraph

Trial report in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06396416. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06396416 phase4recruiting

Obesity Management for Kidney TRANSPLANTation: a Vanguard Study for an Innovative Randomized Controlled Trial, Embedded in Routine Care (OK-TRANSPLANT 2)

Ran2024Enrolled60Registered outcomes20Posted comparisons0ConditionsChronic Kidney Disease, ObesityArmssemaglutide, Virtual Weight Management Coaching
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kristin K ClemensSchulich School of Medicine, Western University, London, Ontario, Canada kristin.clemens@sjhc.london.on.ca.ORCID 0000-0001-9636-5597
Jennifer IrwinFaculty of Health Sciences, Western University, London, Ontario, Canada.
Michael ChiuLondon Health Sciences Centre, London, Ontario, Canada.
Stephanie DixonSchulich School of Medicine, Western University, London, Ontario, Canada.
Natalie J BendoLawson Research Institute, London, Ontario, Canada.
Phil VarugheseLawson Research Institute, London, Ontario, Canada.
Amanda J VinsonNephrology, Dalhousie University, Halifax, Nova Scotia, Canada.
Heather LapierLawson Research Institute, London, Ontario, Canada.
David AttallaYork Weight Loss Clinic, Toronto, Ontario, Canada.
Jaclyn ErnstSchulich School of Medicine, Western University, London, Ontario, Canada.
Tayyab KhanSchulich School of Medicine, Western University, London, Ontario, Canada.
Ann YoungNephrology, Unity Health Toronto, Toronto, Ontario, Canada.
Kevin YauNephrology, University Health Network, Toronto, Ontario, Canada.
Laura CraigLondon Health Sciences Centre, London, Ontario, Canada.
Sonja ReichertSchulich School of Medicine, Western University, London, Ontario, Canada.
Alp SenerSchulich School of Medicine, Western University, London, Ontario, Canada.
Louise M MoistSchulich School of Medicine, Western University, London, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLarge randomised controlled trials (RCTs) of obesity interventions have excluded those with advanced chronic kidney disease (CKD) including recipients of dialysis. Obesity management is critically important to their health and healthcare, including their ability to access kidney transplant.

objectiveTo describe the vanguard phase of a large, pragmatic, open-label RCT testing the effectiveness of a multi-component weight management programme vs standard of obesity care in advanced CKD.

methodsWe are conducting an open-label RCT evaluating a 26-week multicomponent weight management programme (inclusive of monthly virtual coaching; semaglutide to a maximum dose of 2.0 mg/week; and behavioural, dietary and exercise counselling) for those with advanced CKD. Adults aged 18 years or older with a body mass index ≥35 kg/m

trial registrationNCT06396416.

Indexed as

Kidney Failure, ChronicKidney TransplantationObesityObesity ManagementRenal Insufficiency, ChronicWeight Reduction ProgramsAdultAnti-Obesity AgentsBody Mass IndexFemaleGlucagon-Like Peptide 1HumansMaleSemaglutideAnti-Obesity AgentsGlucagon-Like Peptide 1SemaglutideChronic DiseaseDialysisObesity

Identifiers

PMID42580835

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.